Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Vanessa Zhu, Jürgen Burhenne, Johanna Weiss, Mathias Haag, Ute Hofmann, Matthias Schwab, Stephan Urban, Gerd Mikus, David Czock, Walter E. Haefeli, Antje Blank
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-04-01
Serija:	Frontiers in Pharmacology
Teme:	bulevirtide myrcludex B hepatitis D virus infection drug-drug interaction (DDI) SLCO1B OATP1B
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1128547/full
Oznake:	Označite Brez oznak, prvi označite!